A household fridge with tocilizumab injections stored inside to keep cool before use to help prevent joint damage from arthritis.

The arthritis drug tocilizumab has shown early promise in preventing extreme inflammation in gravely ill COVID-19 patients, according to a French clinical study.
The treatment, which suppresses the body’s natural immune response, was found to reduce “significantly” the number of deaths or life support interventions compared with a control group of patients.
The study, carried out by the Paris university hospital trust (AP-HP), looked at 129 people hospitalised with moderate or severe viral pneumonia, which occurs in 5-10 percent of COVID-19 patients.
Half received two injections of tocilizumab as well as standard treatment with antibiotics, while the control group received only standard treatment.
While the results are yet to be published, those involved in the research said it showed clear “clinical benefit” of tocilizumab treatment.
AP-HP said it had decided to publicise the study before publishing official results “for public health reasons”.
They stressed however that further research was needed on the effectiveness of the drug and the potential for side effects.
Tocilizumab, sold under the brand names Actemra and RoAcemtra, is commonly used to treat rheumatoid arthritis.
It is a lab-synthesised antibody that inhibits against a specific protein receptor involved in the body’s natural immune response.
Researchers believe the drug might be able to stave off a state of heightened immune response known as cytokine storms — where the body’s reaction to a foreign body such as a disease or chemical creates acute inflammation.
Cytokine storms can be deadly and occur in severely ill COVID-19 patients.
Tocilizumab currently costs around 800 euros ($870) per injection.
Several existing drugs, including anti-viral medicines, are currently being trialled worldwide for COVID-19 treatment.
– AFP

Subscribe
Notify of
1 Comment
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
You May Also Like

在地铁里抽电子烟还放上网 三名青少年被判有条件警告

日前三名在地铁里抽电子烟的青少年被判处有条件警告,并需要完成社区康复方案,以及无犯罪12个月。 该三名青少年于今年3月25日时被拍摄到在地铁上抽电子烟,最后视频被上传至社交媒体上。 视频中可见,一群年轻人在地铁里被发现使用类似笔一样的东西,在朋友的衬衫里抽烟。该视频被警方发现,并进行调查。 三名青少年里分别为13岁、16岁和18岁。其中13岁和16岁的少年被判有条件警告,并需要完成社区康复计划,和无犯罪12个月。而另名18岁少年亦因其他犯罪行为,违反《烟草(广告和销售控制)法》,被罚款200元和500元。 卫生科学局表示,将会对拥有和使用被禁止的电子烟,以及相关物品严正以待,并采取执法行动。 “在这种情况下,青少年在禁止吸烟的火车上抽烟,公然藐视法律,无视其他现场通勤者,还将视频上传到社交媒体上故意炫耀违法行为。” 鉴于两位未成年是首次犯罪,他们必须接受社区康复治疗,若在未来12个月内再次犯罪,将可被起诉。 根据《烟草法》,新加坡禁止购买、使用和拥有新款烟草产品和仿制烟草产品的新条例将生效,包括网络或进口烟。若触犯法令,可罚款高达2万元。新款烟草产品和仿制烟草产品,包括电子烟、电子烟管、水烟、咀嚼烟草和无烟烟草产品。 根据现有法令,任何人都不准进口、销售和批发新款烟草产品和仿制烟草产品。触犯条例者可被罚款高达1万元,或坐牢长达6个月,或两者兼施。重犯者可被罚款最高2万新元,或坐牢长达12个月,或两者兼施。 卫生科学局公布,自2018年2月1日期至2020年6月30日,已有1千335人因使用电子烟而被捕。 违例者最高可被处以2千元的罚款。

‘Fix the system’: Indonesia parents seek justice after cough syrup crisis

by Gemma Cahya JAKARTA, INDONESIA — Dinosaur-themed birthday decorations still hang on…

Epidemiologist weighs in on Indonesia’s decision to acquire Sinovac vaccine despite unknown levels of efficacy

JAKARTA, INDONESIA — As many as 1.2 million doses of Sinovac COVID-19…

Petition calls for 30 to 50% of Tengah Forest to be preserved instead of being redeveloped into new township

In the wake of the furror of voices calling for the preservation…